These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 19175362)

  • 1. Safety, tolerability and pharmacokinetics of TAS-108, a novel anti-oestrogen, in healthy post-menopausal Japanese women: a phase I single oral dose study.
    Kumagai Y; Fujita T; Ozaki M; Yokota S; Maeda M; Shida M; Otani Y; Yamaya H; Tsuruta H
    Basic Clin Pharmacol Toxicol; 2009 May; 104(5):352-9. PubMed ID: 19175362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose.
    Yamaya H; Yoshida K; Kuritani J; Yonezawa J; Tsuda M; Shindo T; Nagayama S; Buzdar AU
    J Clin Pharm Ther; 2005 Oct; 30(5):459-70. PubMed ID: 16164493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer.
    Blakely LJ; Buzdar A; Chang HY; Frye D; Theriault R; Valero V; Rivera E; Booser D; Kuritani J; Tsuda M
    Clin Cancer Res; 2004 Aug; 10(16):5425-31. PubMed ID: 15328180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of (7alpha)-21-[4-[(diethylamino) methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol-20-[14C]2-hydroxy-1,2,3-propanetricarboxylate ([14C]TAS-108) and its metabolites after single oral administration to rats bearing 7,12-dimethylbenz(alpha)anthracene-induced mammary tumor.
    Yamaya H; Saeki M; Yoshida K; Shibata J; Yano S; Sato Y; Takao A; Shindo T; Buzdar AU; Nagayama S
    Drug Metab Dispos; 2006 Feb; 34(2):331-8. PubMed ID: 16299166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First human exposure to exogenous single-dose oral estetrol in early postmenopausal women.
    Visser M; Holinka CF; Coelingh Bennink HJ
    Climacteric; 2008; 11 Suppl 1():31-40. PubMed ID: 18464021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer.
    Saeki T; Noguchi S; Aogi K; Inaji H; Tabei T; Ikeda T
    Ann Oncol; 2009 May; 20(5):868-73. PubMed ID: 19150935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAS-108: a novel steroidal antiestrogen.
    Buzdar AU
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):906s-8s. PubMed ID: 15701885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects.
    Ahmad A; Shahabuddin S; Sheikh S; Kale P; Krishnappa M; Rane RC; Ahmad I
    Clin Pharmacol Ther; 2010 Dec; 88(6):814-7. PubMed ID: 20981001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.
    Algorta J; Pena MA; Alvarez A; Maraschiello C; Maruhn D; Windisch M; Mucke HA
    Int J Clin Pharmacol Ther; 2009 Jul; 47(7):483-90. PubMed ID: 19640356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase I study of TAT-59 (a new antiestrogen) in breast cancer. TAT-59 Study Group].
    Nomura Y; Abe O; Enomoto K; Fujiwara K; Tominaga T; Hayashi K; Uchino J; Takahashi M; Hayasaka A; Asaishi K; Okazaki M; Abe R; Kimishima I; Kajiwara T; Haga S; Shimizu T; Miyazaki I; Noguchi M; Yoshida M; Miura S; Taguchi T; Oota J; Sakai K; Kinoshita H; Tashiro H
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):553-61. PubMed ID: 9530362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
    Darwish M; Chang S; Hellriegel ET
    Clin Ther; 2009 Jan; 31(1):108-14. PubMed ID: 19243711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
    Lal R; Sukbuntherng J; Luo W; Chen D; Vu A; Tovera J; Cundy KC
    Clin Ther; 2009 Aug; 31(8):1776-86. PubMed ID: 19808136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady-state pharmacokinetics following application of a novel transdermal estradiol spray in healthy postmenopausal women.
    Morton TL; Gattermeir DJ; Petersen CA; Day WW; Schumacher RJ
    J Clin Pharmacol; 2009 Sep; 49(9):1037-46. PubMed ID: 19628730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety.
    Gardin A; Kucher K; Kiese B; Appel-Dingemanse S
    Drug Metab Dispos; 2009 Apr; 37(4):827-33. PubMed ID: 19144772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg.
    Johansen OE; Qvigstad E
    Adv Ther; 2008 Jun; 25(6):525-51. PubMed ID: 18568306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of levetiracetam XR 500mg tablets.
    Rouits E; Burton I; Guénolé E; Troenaru MM; Stockis A; Sargentini-Maier ML
    Epilepsy Res; 2009 Apr; 84(2-3):224-31. PubMed ID: 19264451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women.
    Labrie F; Cusan L; Gomez JL; Côté I; Bérubé R; Bélanger P; Martel C; Labrie C
    Menopause; 2009; 16(1):30-6. PubMed ID: 18820592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest.
    Zeun S; Lu M; Uddin A; Zeiler B; Morrison D; Blode H
    Eur J Contracept Reprod Health Care; 2009 Jun; 14(3):221-32. PubMed ID: 19565420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.